e-SPACE Cardio-Renal-Metabolic 2022: On-demand
Published: 11 April 2022
-
Views:
20256
-
Likes:
7
-
Views:
20256
-
Likes:
7
-
Up Next -
9m 10sPart 6 | Session 3 3.2: Focus on cardiology
-
7m 30sPart 6 | Session 4 3.3: Focus on nephrology
-
33m 58sPart 6 | Session 5 Panel Discussion
-
1m 13sPart 7 | Session 1 Introduction
-
7m 28sPart 7 | Session 2 The meaning of Hemoglobin A1C for the nephrologist
-
8m 10sPart 7 | Session 3 The meaning of Hemoglobin A1C for the cardiologist
-
14m 13sPart 7 | Session 4 Panel discussion
-
2m 6sPart 8 | Session 1 Introduction
-
8m 15sPart 8 | Session 2 4.1: GLP-1RA and CVD in diabetes
-
8m 15sPart 8 | Session 3 4.2: GLP-1 RA and kidney disease in diabetes
-
6m 6sPart 8 | Session 4 4.3: Obesity and cardio-metabolic disease: Role of GLP-1RA
-
1m 6sPart 9 | Session 1 Welcome and introduction
-
5m 20sPart 9 | Session 2 Cardio-renal-metabolic disease in a nutshell
-
6m 45sPart 9 | Session 3 SGLT2 inhibitors in patients with type 2 diabetes and comorbidities
-
6m 42sPart 9 | Session 4 SGLT2 inhibitors in patients with heart failure and comorbidities
-
5m 2sPart 9 | Session 5 SGLT2 inhibitors in patients with chronic kidney disease and comorbidities
-
13m 56sPart 9 | Session 6 Panel discussion
-
1m 39sPart 10 | Session 1 Introduction
-
8m 59sPart 10 | Session 2 5.1: Diagnosis, pathophysiology, epidemiology
-
10mPart 10 | Session 3 5.2: Diabetes
-
8m 6sPart 10 | Session 4 5.3: In chronic kidney disease
-
7m 3s
-
25m 14sPart 10 | Session 6 Panel discussion
-
1mPart 11 | Session 1 Introduction
-
7m 24sPart 11 | Session 2 Mechanism of disease interplay between CVD and CKD
-
9m 6sPart 11 | Session 3 The use of SGLT2is in patients with CKD and CVD with and without diabetes
-
13m 6sPart 11 | Session 4 Panel discussion
-
1m 15sPart 13 | Session 1 Introduction
-
8m 21sPart 13 | Session 2 6.1: EMPEROR-Preserved
-
8m 55sPart 13 | Session 3 6.2: Preserved HF
-
7m 33sPart 13 | Session 4 6.3: Dronedarone in AF management: A 2022 update
-
10m 41sPart 13 | Session 5 6.4: Upcoming trials in 2022 (Deliver, Diamond, Iron Man)
-
24m 16sPart 13 | Session 6 Panel discussion
-
52sPart 15 | Session 1 Introduction
-
5m 46sPart 15 | Session 2 The case for early identification, risk stratification and treatment of CKD
-
5m 24sPart 15 | Session 3 Protecting the kidney and the heart: the cardiologist's perspective
-
6m 52sPart 15 | Session 4 Identifying high-risk patients: the primary care physician's perspective
-
11m 16sPart 15 | Session 5 Panel discussion
-
57sPart 16 | Session 1 Welcome and introduction
-
8m 59sPart 16 | Session 2 8.1: Cachexia in CV disease
-
8m 30sPart 16 | Session 3 8.2: Cachexia in CKD
-
8m 37sPart 16 | Session 4 8.3: Muscle wasting in stroke
-
31m 48sPart 16 | Session 5 Panel discussion
-
28m 46s
-
1m 44sPart 18 | Session 1 Introduction
-
7m 46sPart 18 | Session 2 9.1: Diabetes and CVD today
-
3m 53sPart 18 | Session 3 9.2: Diabetes and kidney today
-
7m 30sPart 18 | Session 4 9.3: The cross-talk between kidney and heart
-
7m 23sPart 18 | Session 5 9.4: Therapeutic solution
-
24m 37sPart 18 | Session 6 Panel discussion
-
30m 11sPart 19 | Session 1 SGLT2 inhibition in the comorbid CKD patient
-
4m 26sPart 19 | Session 2 Panel discussion
-
2m 10sPart 20 | Session 1 Introduction
-
8m 29sPart 20 | Session 2 10.1: Screening of kidney disease
-
8m 11sPart 20 | Session 3 10.2: Screening of heart failure
-
8m 15sPart 20 | Session 4 10.3: Horizons opened by the screening
-
33m 48sPart 20 | Session 5 Panel discussion
-
1m 14sPart 21 | Session 1 Welcome and introduction
-
9m 27sPart 21 | Session 2 New developments in SGLT2 inhibitor use in HFrEF and HFpEF
-
9m 15sPart 21 | Session 3 Implementing guidelines in clinical practice
-
10m 43sPart 21 | Session 4 Panel discussion
-
2m 7sPart 22 | Session 1 Introduction
-
8m 22sPart 22 | Session 2 In ambulatory HFrEF and HFpEF
-
8m 22sPart 22 | Session 3 When to start after acute decompensation
-
9m 38sPart 22 | Session 4 Improving QoL and symptoms
-
2m 24sPart 22 | Session 5 The case of acute MI
-
24m 22sPart 22 | Session 6 Panel discussion
-
50sPart 24 | Session 1 Introduction
-
8m 22sPart 24 | Session 2 Practical issues of managing weight loss in CRM disease: the therapeutic options
-
8m 9sPart 24 | Session 3 Managing weight loss in CRM disease: the nephrologist's perspective
-
8m 31sPart 24 | Session 4 Managing weight loss in CRM disease: the diabetologist's perspective
-
8m 33sPart 24 | Session 5 Managing weight loss in CRM disease: the cardiologists' perspective
-
25m 47sPart 24 | Session 6 Panel discussion
-
1m 30sPart 25 | Session 1 Welcome and introduction
-
16m 6s
-
16m 1sPart 25 | Session 3 Interactive panel discussion
-
31m 2s
-
2m 39sPart 27 | Session 1 Introduction
-
6m 32sPart 27 | Session 2 DAPA CKD: Key lessons from subgroup analyses
-
6m 41sPart 27 | Session 3 FIDELIO/FIGARO DKD
-
8m 34sPart 27 | Session 4 FIDELITY - Main lessons including subgroup analyses
-
11m 1sPart 27 | Session 5 Chlortalidone in CKD stage 4: A new look at an old drug
-
25m 1sPart 27 | Session 6 Panel discussion
-
2m 1sPart 28 | Session 1 Introduction
-
4m 33sPart 28 | Session 2 Screening and diagnosis best practices
-
5m 48sPart 28 | Session 3 Primary care perspective and challenges
-
10m 3sPart 28 | Session 4 Reducing CV risks and new treatment options: case discussion
-
17m 19sPart 28 | Session 5 Panel discussion
-
1m 23sPart 29 | Session 1 Introduction
-
8m 38sPart 29 | Session 2 Digital technologies in CV disease
-
7m 39sPart 29 | Session 3 Remote monitoring of HF
-
34m 11sPart 29 | Session 4 Panel discussion
-
5m 21sPart 30 | Session 1 Introduction
-
8m 24sPart 30 | Session 2 Ascend D and ASCEND ND
-
7m 42sPart 30 | Session 3 The moving field of drug nephrotoxicity
-
8m 22sPart 30 | Session 4 The role of new potassium binding agents in cardio-renal medicine
-
31m 33sPart 30 | Session 5 Panel discussion
-
32m 21s
-
1m 50sPart 32 | Session 1 Introduction
-
6m 50sPart 32 | Session 2 Cardio-centric approach
-
9m 15sPart 32 | Session 3 Gluco-centric approach
-
15m 19sPart 32 | Session 4 Combination therapy as starting option
-
27m 15sPart 32 | Session 5 Panel discussion
-
31m 10sPart 1 Meet the Expert: IgA nephropathy: current optimal management Sydney Tang
-
55sPart 2 | Session 1 Welcome and introduction
-
9m 28sPart 2 | Session 2 1.1: BP in CKD Guidelines
-
8m 48sPart 2 | Session 3 1.2: Diabetes and CKD GL
-
7m 30sPart 2 | Session 4 1.3: General management of the nephrotic syndrome
-
31m 57sPart 2 | Session 5 Panel Discussion
-
1m 4sPart 3 | Session 1 Welcome and Introduction Ewa Jankowska
-
8m 2sPart 3 | Session 2 Management of iron deficiency in heart failure: new evidence, new guidelines
-
10m 31sPart 3 | Session 3 Iron deficiency in chronic kidney disease: why iron matters beyond anaemia
-
11m 28sPart 3 | Session 4 Interactive panel discussion
-
1m 29sPart 4 | Session 1 Introduction Vijay Chopra, Marco Metra
-
16m 37sPart 4 | Session 2 2.1: The new ESC HF guidelines
-
8m 23sPart 4 | Session 3 2.2: Personalised management
-
9m 7sPart 4 | Session 4 2.3: Preventive cardiology
-
25m 36sPart 4 | Session 5 Panel Discussion
-
1m 9sPart 6 | Session 1 Introduction Andrew JS Coats, Alice Cheng
Overview
e-SPACE CARDIO-RENAL-METABOLIC 2022, held on 4-6 March 2022, was the second edition of the global online conference on cardio renal metabolic diseases.
The organisers, under the direction of a world-renowned scientific committee, brought together leading experts in cardiology, nephrology, and diabetology to share clinical practice strategies in treating the inter-related diseases now affecting hundreds of millions people worldwide.
This on-demand version of the event comprises:
- Presentations and discussions with leading experts
- Evidence-based management strategies for diabetes, cardiovascular disease, heart failure, kidney disease & obesity
- Insight to SLGT2i, GLP-1RA and other emerging therapies
- 'Meet the Expert' sessions
e-SPACE Cardio-Renal-Metabolic 2022 was supported by the following companies:
More from this programme
Part 1
Meet the Expert: IgA nephropathy: current optimal management
Part 2
Session 1: The new KDIGO guidelines
Part 3
Industry Session: Iron deficiency in heart failure and kidney disease: interdisciplinary crosstalk
Supported by an unrestricted educational grant from Vifor Pharma
Part 4
Session 2: Recent CV guidelines and treatment algorithms
Part 5
Meet the Experts: NAFLD/NASH as a metabolic disease: improving patients outcomes
Part 6
Session 3: Management of SGLT2 a practical approach
Part 7
Meet the Experts: The meaning of Hemoglobin A1C for the nephrologist and the cardiologist
Part 8
Session 4: GLP-1RA and cardio-metabolic disease in diabetes
Part 9
Industry Session: SGLT2 inhibitors in cardio-renal-metabolic disease: optimizing the patient's journey
Supported by an independent educational grant from Boehringer Ingelheim & Eli Lilly Alliance
Part 10
Session 5: HFpEF: tackling a multidisciplinary problem
Part 11
Meet the Experts: CKD progression in CVD screening and follow-up
Part 12
Meet the Experts: CV, mortality & kidney outcomes with GLP-1 AR in patients with T2DM
Part 13
Session 6: New trial update in cardiology
Part 14
Meet the Experts: The HF Diabetic patient with CKD: optimizing care for a high-risk group
Part 15
Meet the Expert: Multidisciplinary management of cardio-renal-metabolic disease: focus on the kidney
Part 16
Session 8: Sarcopenia, frailty malnutrition and cachexia
Part 17
Meet the Expert: HIF PHI: What do we know and don't know in 2022
Part 18
Session 9: The cardio-kidney interaction: relevance to diabetes
Part 19
Industry Session: SGLT2 inhibition in the comorbid CKD patient
Satellite Symposium supported by an unrestricted educational grant from AstraZeneca
Part 20
Session 10: Why and how to screen for heart failure and kidney disease in diabetes
Part 21
Meet the Expert: SGLT2 inhibitors in heart failure: Improving outcomes across the spectrum of the disease
Part 22
Session 11: SGLT2 inhibition in clinical practice
Part 23
Meet the Expert: The meaning of eGFR for the cardiologists and diabetologist
Part 24
Session 12: Managing obesity in the CRM setting
Part 25
Meet the Experts: Personalized care of patients with heart failure: hyperkalemia as a barrier to optimal medical therapy
Part 26
Meet the Expert: SGLT2, the statin of the 21st century
Part 27
Session 13: New trial update in nephrology
Part 28
Meet the Experts: Reducing the risk of cardiovascular events for patients with CKD and T2DM: new treatment options
Part 29
Session 14: Telemedicine in CRM
Part 30
Session 15: New drugs, new hopes and sometimes risks
Part 31
Meet the Expert: Management of worsening HF
Part 32
Session 16: Harmonising the gluco-and cardio-centric management of diabetes
Faculty Biographies
Andrew JS Coats
Professor of Cardiology and Scientific Director
Prof Coats is Editor-in-Chief of the Cardiac Failure Review journal. He has published over 20 patents, more than 750 full research papers and more than 120,000 career citations and has a personal H-index of 146. Andrew was elected to the Presidential Trio of the Heart Failure Association of the ESC in 2018 and will serve as its president from 2020-2022.
Prof Coats is the Immediate past-President of the Heart Failure Association and past-Professor of Cardiology at the University of Warwick, UK. He has also held posts as Head of Cardiology at Imperial College, London and Associate Medical Director and Director of Cardiology at the Royal Brompton and Harefield Hospitals, London. From 2012 to 2017 he was Director of the Monash-Warwick Alliance, and before that served as Deputy Vice-Chancellor and Dean of Medicine at the University of Sydney.
He is an…
Alice Cheng
Endocrinologist
Dr Alice Cheng is an Associate Professor at University of Toronto, Toronto, CA and Endocrinologist at Trillium Health Partners.
Dr Cheng has been involved with the development of the Diabetes Canada clinical practice guidelines since 2003 and served as Chair for the 2013 version.